Targeting the LMP1-ALIX axis in EBV⁺ nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti-tumor immunity

Abstract

Background: Immunotherapy has revolutionized the therapeutical regimen for nasopharyngeal carcinoma (NPC), yet its response rate remains insufficient. Programmed death-ligand 1 (PD-L1) on small extracellular vesicles (sEVs) mediates local and peripheral immunosuppression in tumors, and the mechanism of PD-L1 loading into these vesicles is garnering increasing attention. Latent membrane protein 1 (LMP1), a key viral oncoprotein expressed in Epstein-Barr virus (EBV)-positive NPC, contributes to remodeling the tumor microenvironment. However, the precise mechanisms by which LMP1 modulates tumor immunity in NPC remain unclear. Here, we aimed to investigate the roles and regulatory mechanisms of LMP1 and sEV PD-L1 in NPC immune evasion.

Methods: We analyzed the impact of LMP1 on tumor-infiltrating lymphocyte abundance in NPC tissues and humanized tumor-bearing mouse models using multiplex immunofluorescence (mIF) and flow cytometry, respectively. Transmission electron microscopy and nanoparticle tracking analysis were employed to characterize sEVs. Immunoprecipitation-mass spectrometry was utilized to identify proteins interacting with LMP1. The regulatory effects of sEVs on tumor microenvironment were assessed by monitoring CD8⁺ T cell proliferation and interferon-γ (IFN-γ) expression via flow cytometry. Furthermore, the expression patterns of LMP1 and downstream regulators in NPC were analyzed using mIF and survival analysis.

Results: High LMP1 expression in NPC patient specimens and mouse models was associated with restricted infiltration of CD8⁺ T cells. Additionally, LMP1 promoted sEV PD-L1 secretion, leading to inhibition of CD8⁺ T cell viability and IFN-γ expression in vitro. Mechanistically, LMP1 recruited apoptosis-linked gene 2-interacting protein X (ALIX) through its intracellular domain and bound PD-L1 through its transmembrane domain, thereby facilitating the loading of PD-L1 into ALIX-dependent sEVs. Disruption of ALIX diminished LMP1-induced sEV PD-L1 secretion and enhanced the anti-tumor immunity of CD8⁺ T cells both in vitro and in vivo. Moreover, increased expression levels of LMP1 and ALIX were positively correlated with enhanced immunosuppressive features and worse prognostic outcomes in NPC patients.

Conclusion: Our findings uncovered the mechanism by which LMP1 interacts with ALIX and PD-L1 to form a trimolecular complex, facilitating PD-L1 loading into ALIX-dependent sEV secretion pathway, ultimately inhibiting the anti-tumor immune response in NPC. This highlights a novel target and prognostic marker for NPC immunotherapy.

Keywords

Epstein-Barr virus / latent membrane protein 1 / small extracellular vesicle / PD-L1 / ALIX / nasopharyngeal carcinoma

References

[1] He J, Williamson L, Cai K, Wong P, Sturgess A, Taper J, Manolios N. Epstein-Barr virus-related lymphoma in rheumatoid arthritis: implications for long-term usage of immunosuppressive drugs and review of the literature. Intern Med J. 2022; 52(10): 1717-23.

[2] Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019; 394(10192): 64-80.

[3] Yang J, Liu Z, Zeng B, Hu G, Gan R. Epstein-Barr virus-associated gastric cancer: A distinct subtype. Cancer Lett. 2020; 495: 191-9.

[4] Xu M, Yao Y, Chen H, Zhang S, Cao SM, Zhang Z, et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat Genet. 2019; 51(7): 1131-6.

[5] Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021; 18(11): 679-95.

[6] Jin S, Li R, Chen MY, Yu C, Tang LQ, Liu YM, et al. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Res. 2020; 30(11): 950-65.

[7] Ding X, Zhang WJ, You R, Zou X, Wang ZQ, Ouyang YF, et al. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2023; 41(14): 2571-82.

[8] Xu JY, Wei XL, Wang YQ, Wang FH. Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol. 2022; 14: 17588359221096214.

[9] Xu JY, Wei XL, Ren C, Zhang Y, Hu YF, Li JY, et al. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy. JAMA Netw Open. 2022; 5(3): e220587.

[10] Wang LW, Jiang S, Gewurz BE. Epstein-Barr Virus LMP1-Mediated Oncogenicity. J Virol. 2017; 91(21): e01718-16.

[11] Wang L, Ning S. New Look of EBV LMP1 Signaling Landscape. Cancers (Basel). 2021; 13(21): 5451.

[12] Lomakin YA, Shmidt AA, Bobik TV, Chernov AS, Pyrkov AY, Aleksandrova NM, et al. Analysis of Immunogenicity of Intracellular CTAR Fragments of Epstein-Barr Virus Latent Phase Protein LMP1. Bull Exp Biol Med. 2017; 163(6): 766-71.

[13] Mosialos G, Birkenbacht M, Yalamanchill R, Arsdale TV, Ware C, Kleff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995; 80(3): 389-99.

[14] Zhao B. Epstein-Barr Virus B Cell Growth Transformation: The Nuclear Events. Viruses. 2023; 15(4): 832.

[15] Lavorgna A, Harhaj EW. EBV LMP1: New and shared pathways to NF-κB activation. Proc Natl Acad Sci USA. 2012; 109(7): 2188-9.

[16] Wang L, Howell MEA, Sparks-Wallace A. Zhao J, Hensley CR, Nicksic CA, et al. The Ubiquitin Sensor and Adaptor Protein p62 Mediates Signal Transduction of a Viral Oncogenic Pathway. mBio. 2021; 12(5): e0109721.

[17] Giehler F, Ostertag MS, Sommermann T, Weidl D, Sterz KR, Kutz H, et al. Epstein-Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex. Nat Commun. 2024; 15(1): 414.

[18] Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget. 2014; 5(23): 12189-202.

[19] Bi XW, Wang H, Zhang WW, hua WJ, jian LW, jun XZ, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016; 9: 109.

[20] Choi IK, Wang Z, Ke Q, Hong M, Paul DW, Fernandes SM, et al. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature. 2021; 590(7844): 157-62.

[21] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020; 367(6478): eaau6977.

[22] Welsh JA, Goberdhan DCI, O’Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024; 13(2): e12404.

[23] Tang Q, Yang S, He G, Zheng H, Zhang S, Liu J, et al. Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. Cancer Lett. 2022; 548: 215823.

[24] Kugeratski FG, Kalluri R. Exosomes as mediators of immune regulation and immunotherapy in cancer. FEBS J. 2021; 288(1): 10-35.

[25] Migliano SM, Wenzel EM, Stenmark H. Biophysical and molecular mechanisms of ESCRT functions, and their implications for disease. Curr Opin Cell Biol. 2022; 75: 102062.

[26] Bissig C, Gruenberg J. ALIX and the multivesicular endosome: ALIX in Wonderland. Trends Cell Biol. 2014; 24(1): 19-25.

[27] Larios J, Mercier V, Roux A, Gruenberg J. ALIX-and ESCRT-III-dependent sorting of tetraspanins to exosomes. J Cell Biol. 2020; 219(3): e201904113.

[28] Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012; 14(7): 677-85.

[29] Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018; 560(7718): 382-6.

[30] Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019; 177(2): 414-427.e13.

[31] Morrissey SM, Yan J. Exosomal PD-L1: Roles in tumor progression and immunotherapy. Trends Cancer. 2020; 6(7): 550-8.

[32] Jasinski-Bergner S, Mandelboim O, Seliger B. Molecular mechanisms of human herpes viruses inferring with host immune surveillance. J Immunother Cancer. 2020; 8(2): e000841.

[33] Cao Y, Xie L, Shi F, Tang M, Li Y, Hu J, et al. Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study. Sig Transduct Target Ther. 2021; 6(1): 1-33.

[34] Zhou Y, Shi D, Miao J, Wu H, Chen J, Zhou X, et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. Sci Rep. 2017; 7: 43627.

[35] Nkosi D, Sun L, Duke LC, Meckes DG. Epstein-Barr virus LMP1 manipulates the content and functions of extracellular vesicles to enhance metastatic potential of recipient cells. PLoS Pathog. 2020; 16(12): e1009023.

[36] Nkosi D, Sun L, Duke LC, Patel, N., Surapaneni, SK, Singh, M., et al. Epstein-Barr Virus LMP1 Promotes Syntenin-1-and Hrs-Induced Extracellular Vesicle Formation for Its Own Secretion To Increase Cell Proliferation and Migration. mBio. 2020; 11(3): e00589-20.

[37] Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol. 2013; 200(4): 373-83.

[38] Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020; 20(4): 209-15.

[39] Greening DW, Gopal SK, Xu R, Simpson RJ, Chen W. Exosomes and their roles in immune regulation and cancer. Semin Cell Dev Biol. 2015; 40: 72-81.

[40] Verweij FJ, de Heus C, Kroeze S, Cai H, Kieff E, Piersma SR, et al. Exosomal sorting of the viral oncoprotein LMP1 is restrained by TRAF2 association at signalling endosomes. J Extracell Vesicles. 2015; 4: 26334.

[41] Lo AKF, Dawson CW, Lung HL, Wong KL, Young LS. The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy. Front Oncol. 2021; 11: 640207.

[42] Choi IK, Wang Z, Ke Q, Hong M, Paul DW, Fernandes SM, et al. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature. 2021; 590(7844): 157-62.

[43] Kase K, Kondo S, Wakisaka N, Dochi, H., Mizokami, H., Kobayashi, E., et al. Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma. Microorganisms. 2021; 9(3): 603.

[44] Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020; 20(4): 209-15.

[45] Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016; 9(1): 109.

[46] Cortes-Galvez D, Dangerfield JA, Metzner C. Extracellular Vesicles and Their Membranes: Exosomes vs. Virus-Related Particles. Membranes. 2023; 13(4): 397.

[47] Shin K, Kim J, Park SJ, Lee MA, Park JM, Choi MG, et al. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy. Sci Rep. 2023; 13(1): 6952.

[48] Rider MA, Cheerathodi MR, Hurwitz SN, Nkosi D, Howell LA, Tremblay DC, et al. The interactome of EBV LMP1 evaluated by proximity-based BioID approach. Virology. 2018; 516: 55-70.

[49] Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol. 1996; 16(12): 7098-108.

[50] Martin-Serrano J, Marsh M. ALIX Catches HIV. Cell Host Microbe. 2007; 1(1): 5-7.

[51] Zhai Q, Landesman MB, Robinson H, Sundquist WI, Hill CP. Identification and Structural Characterization of the ALIX-Binding Late Domains of Simian Immunodeficiency Virus SIVmac239 and SIVagmTan-1. J Virol. 2011; 85(1): 632-7.

RIGHTS & PERMISSIONS

2024 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.